Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
Sign Up to like & getrecommendations! Published in 2020 at "Inflammatory Bowel Diseases"
DOI: 10.1093/ibd/izaa199
Abstract: Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development… read more here.
Keywords: tofacitinib oral; program; malignancy; kinase inhibitor ... See more keywords
THU0171 TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS – THE RESULTS OF RUSSIAN NATIONAL REGISTER OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.5986
Abstract: Background: Tofacitinib (TF) is an oral Janus Kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objectives: To evaluate the one-year effectiveness of tofacitinib as first-line therapy in RA conventional synthetic (cs) DMARDs non-responders. Methods:… read more here.
Keywords: none declared; tofacitinib oral; treatment; treated tofacitinib ... See more keywords